Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

StemBANCC at the start – funded with EUR 55.6 M

18.12.2012
StemBANCC will start yet this year – an international research project involving 25 academic partners and 11 partners from the pharmaceutical industry.
Funded with a total budget of EUR 55.6 M, StemBANCC intends to develop new therapies for Alzheimer’s, Parkinson’s, diabetes and other major diseases. The 5-year project relies on knowledge from stem cell research, for improved active ingredients, and it will build a platform with a total of 1500 pluripotent stem cell lines, also known as induced pluripotent stem cells or iPS. For this iPS technology, the Nobel Prize in Medicine was awarded this year. NMI’s contribution to StemBANCC is its expertise in the field of electro-physiology.

Headed by Prof. Dr. Elke Guenther, head of the cell biology division at the NMI, her team of researchers is responsible for characterising the functioning of the stem cells and their pharmacological validation.

Currently, many drugs fail rather late in the drug development process because the tests used in the earlier stages of drug development simply do not reflect what happens in real life when the drug is administered in patients. This is partly because these early tests rely heavily on animal cells, and when human cells are used, they have often been extensively modified to survive in culture and so no longer behave naturally. Those working in drug research and development therefore urgently need a good supply of cells that more accurately mimic what happens in the human body.

The power of pluripotency
Most adult cells can only divide to produce other cells of the same type – for example, skin cells can only make other skin cells, and blood cells can only make other blood cells. Only embryonic stem cells are ‘pluripotent’, i.e. able to give rise to all the different kinds of cell that make up the human body. However, in recent years researchers have developed a way of reprogramming ordinary adult cells to create so-called induced pluripotent stem (iPS) cells. Like embryonic stem cells, iPS cells are able to generate any kind of cell; as such, they offer researchers a good supply of different kinds of human cell that can be used in research and drug development. The research resulting in the creation of the first iPS cells was a major scientific breakthrough that won scientists John Gurdon and Shinya Yamanaka the 2012 Nobel Prize in Physiology or Medicine.

A unique resource

STEMBANCC’s goal is to generate 1 500 iPS cell lines from 500 people, characterise them in terms of their genetic, protein, and metabolic profiles, and make them available to researchers. All cell lines will also undergo a rigorous quality check.

The raw materials for the project will be largely skin and blood samples taken from patients with certain diseases, people who display adverse reactions to drugs, and healthy individuals. The collection of these samples will be carried out with the individuals’ informed consent and in line with strict ethical standards.

There will be a strong focus on peripheral nervous system disorders (especially pain); central nervous system disorders (e.g. dementias); neurodysfunctional diseases (e.g. migraine, autism, schizophrenia, and bipolar disorder); and diabetes. The project will also investigate the use of human iPS cells for toxicology testing; here the team will use the iPS cells to generate liver, heart, nerve and kidney cells.

Ultimately STEMBANCC will be a source of well-characterised, patient-derived iPS cells that will help researchers study diseases, develop new treatments, and test the efficacy and safety of new drugs.

The Innovative Medicines Initiative
The Innovative Medicines Initiative (IMI) is Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe. IMI is a joint undertaking between the European Union and the pharmaceutical industry association EFPIA. www.imi.europa.eu

The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n°115439, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution.

Dr. Nadja Gugeler | idw
Further information:
http://www.nmi.de/
http://www.biochipnet.com/

More articles from Awards Funding:

nachricht RNA: a vicious pathway to cancer ?
14.08.2017 | Goethe-Universität Frankfurt am Main

nachricht Extensive Funding for Research on Chromatin, Adrenal Gland, and Cancer Therapy
28.06.2017 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt

All articles from Awards Funding >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

Im Focus: Scientists improve forecast of increasing hazard on Ecuadorian volcano

Researchers from the University of Miami (UM) Rosenstiel School of Marine and Atmospheric Science, the Italian Space Agency (ASI), and the Instituto Geofisico--Escuela Politecnica Nacional (IGEPN) of Ecuador, showed an increasing volcanic danger on Cotopaxi in Ecuador using a powerful technique known as Interferometric Synthetic Aperture Radar (InSAR).

The Andes region in which Cotopaxi volcano is located is known to contain some of the world's most serious volcanic hazard. A mid- to large-size eruption has...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

New thruster design increases efficiency for future spaceflight

16.08.2017 | Physics and Astronomy

Transporting spin: A graphene and boron nitride heterostructure creates large spin signals

16.08.2017 | Materials Sciences

A new method for the 3-D printing of living tissues

16.08.2017 | Interdisciplinary Research

VideoLinks
B2B-VideoLinks
More VideoLinks >>>